[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sonrotoclax\" }]"}]},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/cll.ts","type":"changed","fields":[{"field":"tldr","before":"\"A more potent, shorter-acting successor to venetoclax. Approved for mantle cell lymphoma in May 2026 and in late-stage trials with zanubrutinib for CLL.\"","after":"\"Sonrotoclax is a more potent, shorter-acting successor to venetoclax. It was approved for mantle cell lymphoma in May 2026 and is in late-stage trials with zanubrutinib for CLL.\""}]},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","commit":"713bfbdd72","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: AML, ALL, CLL deep dives (102 new entities: trials with structured outcomes, products with dosing/toxicity/regulatory events, target","file":"src/data/spikes/cll.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"code"},{"field":"modality"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"pathways"},{"field":"terms"},{"field":"related"}]}]